Cipla CEO On Lung Leadership Beyond Asthma, AMR Plans

CEO Vohra Talks Strategy With Scrip

CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.  

Cipla CEO
Cipla CEO Umang Vohra

Cipla Limited’s lung leadership aspirations go well beyond its traditional stronghold of asthma and could encompass domains like oncology, alongside repurposing initiatives and breaking into new markets.

In an exclusive interview with In Vivo's sister publication Scrip, the Indian firm’s global CEO and managing director Umang Vohra...

More from Business Strategy

More from In Vivo